About Alentis Therapeutics
Alentis Therapeutics is a company based in Basel (Switzerland) founded in 2019 by Thomas Baumert.. Alentis Therapeutics has raised $365.66 million across 4 funding rounds from investors including Schroders, Orbimed and Bpifrance. Alentis Therapeutics offers products and services including ADC ALE.P02 and Lixudebart. Alentis Therapeutics operates in a competitive market with competitors including argenx, MacroGenics, Alexion, Zai Lab and Kodiak Sciences, among others.
- Headquarter Basel, Switzerland
- Founders Thomas Baumert
- Stage Unicorn
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Alentis Therapeutics Ag
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$365.66 M (USD)
in 4 rounds
-
Latest Funding Round
$181.4 M (USD), Series D
Nov 12, 2024
-
Investors
Schroders
& 13 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Alentis Therapeutics
Alentis Therapeutics offers a comprehensive portfolio of products and services, including ADC ALE.P02 and Lixudebart. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Antibody-drug conjugate targeting squamous cancers for selective tumor cell killing.
Monoclonal antibody designed to reverse organ fibrosis through Claudin-1 targeting.
Unlock access to complete
Unlock access to complete
Funding Insights of Alentis Therapeutics
Alentis Therapeutics has successfully raised a total of $365.66M across 4 strategic funding rounds. The most recent funding activity was a Series D round of $181.4 million completed in November 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 4
- Last Round Series D — $181.4M
-
First Round
First Round
(29 Apr 2019)
- Investors Count 14
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov, 2024 | Amount | Series D - Alentis Therapeutics | Valuation | Orbimed , Novo Holdings | |
| Apr, 2023 | Amount | Series C - Alentis Therapeutics | Valuation | Jeito , Novo Holdings | |
| Jun, 2021 | Amount | Series B - Alentis Therapeutics | Valuation | Morningside |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Alentis Therapeutics
Alentis Therapeutics has secured backing from 14 investors, including venture fund and institutional investors. Prominent investors backing the company include Schroders, Orbimed and Bpifrance. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
|
Founded Year | Domain | Location | |
|
Private equity and venture capital fund focused on the healthcare sector
|
Founded Year | Domain | Location | |
|
Jeito Capital is focused on financing medical innovation globally.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Alentis Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Alentis Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Alentis Therapeutics Comparisons
Competitors of Alentis Therapeutics
Alentis Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as argenx, MacroGenics, Alexion, Zai Lab and Kodiak Sciences, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment.
|
|
| domain | founded_year | HQ Location |
A biopharmaceutical company focused on cancer therapeutics development.
|
|
| domain | founded_year | HQ Location |
Therapies for rare and devastating diseases are developed by Alexion.
|
|
| domain | founded_year | HQ Location |
Antibody-based therapies for cancers and inflammatory diseases are developed.
|
|
| domain | founded_year | HQ Location |
Therapeutics for retinal diseases are developed by the company.
|
|
| domain | founded_year | HQ Location |
Antibody therapies are developed through machine learning and synthetic biology.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Alentis Therapeutics
Frequently Asked Questions about Alentis Therapeutics
When was Alentis Therapeutics founded?
Alentis Therapeutics was founded in 2019.
Where is Alentis Therapeutics located?
Alentis Therapeutics is headquartered in Basel, Switzerland. It is registered at Basel, Basel-stadt, Switzerland.
Who is the current CEO of Alentis Therapeutics?
Roberto Iacone is the current CEO of Alentis Therapeutics.
Is Alentis Therapeutics a funded company?
Alentis Therapeutics is a funded company, having raised a total of $365.66M across 4 funding rounds to date. The company's 1st funding round was a Series B of $67M, raised on Apr 29, 2019.
What does Alentis Therapeutics do?
Alentis Therapeutics was founded in 2019 in Basel, Switzerland. Focus is placed on developing treatments for fibrosis, cirrhosis, and liver cancer within the biotechnology sector. A gene expression platform supports the advancement of monoclonal antibodies targeting the CLDN1 protein. These are investigated for advanced liver fibrosis, kidney fibrosis, hepatocellular carcinoma, and cholangiocarcinoma. Drug candidates in the pipeline include ALE-F02 and ALE-C04.
Who are the top competitors of Alentis Therapeutics?
Alentis Therapeutics's top competitors include argenx, Zai Lab and Kodiak Sciences.
What products or services does Alentis Therapeutics offer?
Alentis Therapeutics offers ADC ALE.P02 and Lixudebart.
Who are Alentis Therapeutics's investors?
Alentis Therapeutics has 14 investors. Key investors include Schroders, Orbimed, Bpifrance, RA Capital, and Novo Holdings.
What is Alentis Therapeutics's valuation?
The valuation of Alentis Therapeutics is $2B as of Jun 2021.